Tyra Biosciences to host conference call on SURF302 initial results
Tyra Biosciences will host a conference call on initial results for oral dabogratinib from the SURF302 Phase 2 study for IR NMIBC on September 9, 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.